Back to top
more

Veeva Systems (VEEV)

(Real Time Quote from BATS)

$222.18 USD

222.18
527,560

+5.73 (2.65%)

Updated Nov 7, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Internet - Software

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BD (BDX) Introduces New Molecular Diagnostic Platform in US

by Zacks Equity Research

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

GAN Limited (GAN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

GAN Limited (GAN) delivered earnings and revenue surprises of 10% and 11.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection

by Zacks Equity Research

BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.

Ziff Davis (ZD) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ziff Davis (ZD) delivered earnings and revenue surprises of -5.38% and 2.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AudioEye (AEYE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AudioEye (AEYE) delivered earnings and revenue surprises of 25.58% and 1.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

QuinStreet (QNST) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

QuinStreet (QNST) delivered earnings and revenue surprises of -18.18% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Masimo's (MASI) New Product Expansion to Boost Patient Outcome

by Zacks Equity Research

Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.

Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.

Veeva Systems (VEEV) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Veeva (VEEV) delivered earnings and revenue surprises of 2.27% and 1.15%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

Looking for that Perfect 5-Year Earnings Chart?

by Tracey Ryniec

Think that the pandemic has upended most companies' earnings surprise track records? Think again.

    Daniel Laboe headshot

    Time To Buy The Fear Dip?

    by Daniel Laboe

    Innovation's capitulation may be sold out as high-growth bears run out of selling fuel, leaving the door wide open for stock pickers to get into their favorite next-gen stocks

    Veeva Systems (VEEV) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials

    by Zacks Equity Research

    Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

    Cloudflare (NET) Reports Break-Even Earnings for Q4

    by Zacks Equity Research

    Cloudflare (NET) delivered earnings and revenue surprises of 100% and 4.77%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy

    by Zacks Equity Research

    Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.

    Veeva (VEEV) Stock Jumps 3.6%: Will It Continue to Soar?

    by Zacks Equity Research

    Veeva (VEEV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    Why Is Veeva (VEEV) Down 0.9% Since Last Earnings Report?

    by Zacks Equity Research

    Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

    by Zacks Equity Research

    Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

    Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

    Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering

    by Zacks Equity Research

    Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.